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a short questionnaire about socio-demographic data, adherence (Morisky Medica-
tion Adherence Scale) and knowledge (Michigan Diabetes Knowledge Test) while
medical records were reviewed for diabetes-related data. RESULTS: The mean age
was 58.16 years (SD9.16) with around 50% males. The mean MMAS score of the
patients was 6.11 (SD 1.66) and the total mean score of MDKT was 7.44 (SD3.08).
A significant positive correlation between MMAS and MDKT scores were found (n
505, rs  0.456, p  0.001). A significant association between knowledge levels and
adherence levels was found (p0.05). The correlation coefficient between HbA1C
and total knowledge score was – 0.39 (p 0.001). Higher diabetes knowledge was a
significant predictor of higher medication adherence (OR  1.381, p  0.001).
CONCLUSIONS: Medication adherence is moderately related with diabetes knowl-
edge. Deficiencies in patients’ knowledge may be the greatest barriers to improving
adherence and improvement of patients’ knowledge could result in better medica-
tion adherence.
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OBJECTIVES: To evaluate the general practitioners’ (GPs) reasons for prescribing
pioglitazone 15 or 30 mg and characterise the patients on these doses. METHODS:
An internet-based survey was conducted among 245 UK GPs who selected reasons
for prescribing pioglitazone 15 or 30 mg/day for their patients. Eligible patients
were 18 years at type 2 diabetes mellitus (T2DM) diagnosis and currently on
pioglitazone (15 or 30 mg) with other oral antihyperglycaemic agents for 3
months. GPs provided clinical data for1 patient on each pioglitazone dose. The 29
potential reasons for prescribing the current pioglitazone dose were classified into
4 categories: sufficient glycaemic control, poor tolerability and/or side effects as-
sociated with pioglitazone, comorbidity/polypharmacy, and patient-related
factors.RESULTS:Of the 1456 patients provided by GPs, 739 were on pioglitazone 15
mg and 717 on 30 mg. Compared with the 30-mg group, patients in the 15-mg group
had a shorter duration of T2DM (median 7.3 vs. 8.3 years) and the same median
HbA1c level (7.2%). Collectively, reasons in the sufficient glycaemic control category
were selected most for both groups; however, they were selected more often for 15
than 30 mg (85 vs. 75%, p0.0001). Specifically, new user was selected for 26% on
15 mg and 11% on 30 mg (p0.0001). No significant differences between groups
were seen within the other categories. Overall, 37% of GPs selected reasons related
to poor tolerability and/or side effects, 42% for comorbidity/polypharmacy, and
30% for patient-related factors. GPs indicated they had no plans to change the
current pioglitazone dose for 58% on 15 mg and 66% on 30 mg. CONCLUSIONS: UK
GPs in this study appear comfortable with their current pioglitazone dose choice for
their patients and a majority of GPs planned to have their patients continue on
their current pioglitazone dose in combination therapy.
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OBJECTIVES: To explore the utility of a novel Subgroup Identification Tool (SIT) in
a healthcare database; specifically to identify which patient subgroup would
achieve better outcome from which treatment option.METHODS: For the purposes
of this study, two cohorts of patients with type II diabetes were extracted from the
UK General Practice Research Database. Study patients were 40 years old, were
newly prescribed with antidiabetics Drug A or Drug B, and had at least 6-month
pre-index and 12-month post-index history. The index date was defined as the date
of first prescription for Drug A or Drug B. The outcome was the average HbA1c from
3 months post-index to the end of 12-month follow-up. Subgroups were con-
structed using the SIT, which employs a novel SIDES (subgroup identification based
on differential effect search) methodology. RESULTS: A total of 4824 patients were
identified initiating Drug A and 1007 patients initiating Drug B. Slightly more pa-
tients achieved HbA1c7% for Drug A (46.4%) compared with Drug B (42.6%), trans-
lating to the number needed to treat (NNT) of 26 in favor of Drug A. The SIT iden-
tified a subgroup (male, 71 years old without a prescription for antihypertensives)
where the Drug A patients responded more favorably than Drug B in terms of
achieving HbA1c 7% (NNT 8 in favor of Drug A); and a subgroup (female, low
density cholesterol 120mg/dl with a prescription for angiotensin-converting en-
zyme inhibitors) where the Drug-B patients responded more favorably (NNT 10 in
favor of Drug B). CONCLUSIONS: This study indicates that the SIT can be useful
when applied to healthcare data to identify subgroups that are more likely to
achieve better outcome from one of the two comparative treatment options. The
results from the SIT could be used for hypothesis generation. Validation using
independent data is warranted.
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OBJECTIVES: To validate the recently updated Charlson Comorbidity Index (CCI)
for the prediction of healthcare utilization and to compare its predictive power in
patients with diabetes or asthma.METHODS:Data were retrieved from the Medical
Expenditure Panel Survey (MEPS) Panel 12 (2007-2008) for this retrospective cohort
study. The original CCI (CCI-1) and updated CCI (CCI-2) scores were calculated for
patients who had diabetes or asthma in 2007. Adjusted R2 from linear regression
models were used for the estimation of log-transformed healthcare expenditures
(COST) in 2008. C statistics from logistic regression models were used to compare
the predictive power of the risk of hospitalizations ( 1 admission), risk of emer-
gency department visits ( 1 visit), and high expenditures ( 90th percentile of
COST) in 2008. RESULTS: 833 diabetic patients and 704 asthmatic patients were
included in the study. The diabetes cohort had a mean age of 59.7 years (SD: 15.3),
and 54% were female; the asthma cohort had a mean age of 37.8 years (SD: 23.6),
and 59% were female. In the linear regressions, the CCI-2 explained more variance
in COST in diabetic patients than in asthmatic patients (adjusted R2  17.4% vs.
14.1%), adjusting for demographics. The CCI-2 was a better predictor of high COST
(c  0.881 vs. 0.816) and the risk of hospitalization (c  0.713 vs. 0.682) but a poorer
predictor of the risk for an emergency department visit (c  0.583 vs. 0.653) in the
diabetes cohort than in the asthma cohort. In both cohorts, the CCI-2 (c  0.583 to
0.881) exhibited consistently better predictive power than the CCI-1 (c  0.576 to
0.839). CONCLUSIONS: The predictive power of CCI varies depending on the out-
comes of interest in patients with diabetes or asthma. The updated CCI showed
improved predictive performance compared to the original CCI.
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OBJECTIVES: To develop a method to adjust the medication possession ratio (MPR)
for type 2 diabetes patients who used a vial or pen form of insulin.METHODS:Using
a retrospective analysis of large US health claims data from 2003 to 2008, diabetes
patients who had at least two insulin prescription fills during the pre-index period
were selected. The index date was the date of the first fill of insulin during the
identification period from 2004 to 2007. One year of pre- and post-index continuous
enrollment was required. Patients were excluded from the study if they switched to
another form of insulin during the post-index period or had a diagnosis of gesta-
tional diabetes during the pre- or post-index period. MPR was calculated as a mea-
sure of drug adherence for patients who used vial insulin (&#x0018;Vial
Cohort&#x0019;), and for those who used pen form insulin (’Pen Cohort’). Since
insulin is a multi-dose treatment and is available in several package sizes, tradi-
tional MPR calculation is not suitable for this study. We adjusted the MPR by mul-
tiplying the traditional MPR by (average days between prescription refills/average
days’ supply) for patients in both cohorts. RESULTS: The unadjusted MPR during
the post-index period for patients who used the pen device is lower than for pa-
tients who used a vial (0.55 vs. 0.60, p0.0082). After controlling for baseline patient
characteristics as well as the differences in package size between the pen and vial
insulin using the new calculation method, the adjusted MPR for patients in the ’Pen
Cohort’ was higher than for patients in the ’Vial cohort’ (0.22 vs. 0.13, p0.001).
CONCLUSIONS: After modifying the traditional MPR by adjusting the package size
of the pen or vial insulin device, the adjusted MPR showed that pen insulin users
had a significant advantage in drug adherence over vial users.
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OBJECTIVES: The growing prevalence of diabetes mellitus highlights the conflict
between the burden of disease and sustainability of health care systems, especially
in Central-Eastern European middle income countries. Open access health eco-
nomic models that calculate the effects of health policy programs and public in-
terventions can improve the appropriateness of decisions. Our objective was to
develop a long term economic model for type 2 diabetes and make it available for
public sector decision-makers to support evidence based health policy decisions.
METHODS: The health economic model projects outcomes for selected patient
populations, taking into account baseline patient characteristics, history of com-
plications, changes in physiological parameters over time, diabetes treatment and
management strategies, and screening programs. First section of the model exam-
ines secondary prevention strategies of type 2 diabetes in a decision tree structure.
The second section simulates patients through interconnected Markov sub-models
that replicate important complications of diabetes (ischemic heart disease, reti-
nopathy, hypoglycaemia, nephropathy, neuropathy, foot ulcer, peripherial vascu-
lar disease, stroke and ketoacidosis). Treatment and management strategies are
taken into account when modeling patient pathways. The model includes a wide
range of economic and clinical input data to support adaptability, country- or pro-
vider-specific outcomes and the analysis of different policy and treatment
strategies. RESULTS: In this paper we present the methodological approach, the
model structure, main scientific evidences applied and the choice of policy or treat-
ment strategies that can be examined. CONCLUSIONS: Evidence based health pol-
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